New hope for advanced cancer patients as experimental drug SKB105 enters human trials
NCT ID NCT07380386
First seen Feb 02, 2026 · Last updated May 25, 2026 · Updated 9 times
Summary
This study tests a new drug, SKB105, in 256 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has three parts: starting with low doses to check safety, then expanding to more patients, and finally testing in specific tumor types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Email: •••••@•••••
-
Shangahi Chest Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.